Regulation of macrophage functions by macrophage deactivating factor, a tumor cell-derived cytokine

  • C. Bogdan
  • Y. Vodovotz
  • C. F. Nathan
Chapter

Abstract

Upon activation macrophages kill or inhibit growth of both intracellular and extracellular parasites as well as malignant host cells (1–6; for review: 7–11). A number of secretory products of the macrophage, such as reactive oxygen intermediates (ROI), reactive nitrogen intermediates (RNI), tumor necrosis factor a (TNF) and interleukin 1 (IL-1) are believed to mediate — directly or indirectly — the tumoricidal and microbicidal capacity of the macrophage (11). In addition to their effector function macrophages play an important role in the activation of other components of the immune system, such as Thelper cells, cytotoxic T-cells and natural killer cells (12).

Keywords

Visceral Leishma Niasis P815 Cell Reactive Oxygen Inter Reactive Nitrogen Intermediate Resident Peritoneal Macrophage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lurie MB. Studies on the mechanisms of immunity in tuberculosis. The fate of tubercle bacilli ingested by mononuclear phagocytes derived from normal and immunized animals. J Exp Med 1942, 75:247–268.PubMedCrossRefGoogle Scholar
  2. 2.
    Mackaness GB. Cellular resistance to infection. J Exp Med 1962, 116:381–406.PubMedCrossRefGoogle Scholar
  3. 3.
    Mackaness GB. The immunological basis of acquired cellular resistance. J Exp Med 1964, 120:105–120.PubMedCrossRefGoogle Scholar
  4. 4.
    Mackaness GB. The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med 1969, 129:973–992.PubMedCrossRefGoogle Scholar
  5. 5.
    Hibbs JB. Activated macrophages as cytotoxic effector cells. II. Requirement for local persistence of inducing antigen. Transplantation, 1975, 19:81–87.PubMedCrossRefGoogle Scholar
  6. 6.
    Hibbs JB. The macrophage as tumoricidal effector cells: a review of in vitro ans in vivo studies on the mechanism of the activated macrophage nonspecific cytotoxic reaction. In: The Macrophage in Neoplasia. Fink MA, Ed. Academic Press, New York 1976, p. 83.Google Scholar
  7. 7.
    North RJ. The concept of the activated macrophage. J Immunol 1978, 121:806–809.PubMedGoogle Scholar
  8. 8.
    Cohn ZA. The activation of mononuclear phagocytes: fact, fancy and future. J Immunol 1978, 121:813–816.PubMedGoogle Scholar
  9. 9.
    Karnovsky ML, Lazdins JK. Biochemical criteria for activated macrophages. J Immunol 1978, 121:809–813.PubMedGoogle Scholar
  10. 10.
    Adams DO, Hamilton TA. The cell biology of macrophage activation. Annual Rev Immunol 1984, 2:283–318.CrossRefGoogle Scholar
  11. 11.
    Nathan CF. Coordinate actions of growth factors in monocytes/macrophages. In: Handbook of Experimental Pharmacology, Vol. 95/II Peptide Growth Factors and Their Receptors II. Sporn MB, Roberts AB, Eds. Springer Verlag Berlin/Heidelberg 1990, pp. 428–463.Google Scholar
  12. 12.
    Johnston RB Jr. Monocytes and macrophages. New Engl J Med 1988, 318:747–752.PubMedCrossRefGoogle Scholar
  13. 13.
    Nelson DS, Nelson M, Farram E, Inoue Y. Cancer and subversion of host defenses. Austr J Exp Biol Med Sci 1981, 59:229–262.CrossRefGoogle Scholar
  14. 14.
    Englund PT, Sher A, Eds. The biology of parasitism. A molecular and immunological approach. A.R. Liss, New York 1988.Google Scholar
  15. 15.
    Killion JJ, Fidler IJ. Evasion of host responses in metastasis: implications of cellular resistance to cytokines. Curr Opinion Immunol 1990, 2:693–696.CrossRefGoogle Scholar
  16. 16.
    Bogdan C, Röllinghoff M, Solbach W. Evasion strategies of Leishmania parasites. Parasitol Today 1990, 6:183–187.PubMedCrossRefGoogle Scholar
  17. 17.
    Hall BF, Joiner KA. Strategies of obligate intracellular parasites for evading host defenses. In: Immunoparasitology Today. Ash C, Gallagher RB, Eds. Elsevier Trends Journals, Cambridge, UK 1991, pp. A22-A27.Google Scholar
  18. 18.
    Ebert EC, Roberts AI, O’Connell SM, Robertson FM, Nagase H. Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol 1987, 138:2161–2168.PubMedGoogle Scholar
  19. 19.
    Szuro-Sudol A, Nathan CF, Cohn Z. Tumor cell factor inhibits H2O2release from activated macrophages. Fed Proc 1982, 41:962. Abstract.Google Scholar
  20. 20.
    Szuro-Sudol A. Deactivation of macrophages by products of other cells. Thesis. The Rockefeller University, New York, 1985.Google Scholar
  21. 21.
    Szuro-Sudol A, Nathan CF. Suppression of macrophage oxidative metabolism by products of malignant and nonmalignant cells. J Exp Med 1982, 156:945–961.PubMedCrossRefGoogle Scholar
  22. 22.
    Tsunawaki S, Nathan CF. Macrophage deactivation. Altered kinetic properties of superoxide-producing enzyme after exposure to tumor cell-conditioned medium. J Exp Med 1986, 164:1319–1331.PubMedCrossRefGoogle Scholar
  23. 23.
    Srimal S, Nathan C. Purification of macrophage deactivating factor. J Exp Med 1990, 171:1347–1361.PubMedCrossRefGoogle Scholar
  24. 24.
    Tsunawaki S, Sporn M, Nathan CF. Comparison of transforming growth factor-β and a macrophage-deactivating polypeptide from tumor cells. Differences in antigenicity and mechanism of action. J Immunol 1989, 142:3462–3468.PubMedGoogle Scholar
  25. 25.
    Szuro-Sudol A, Murray HW, Nathan CF. Suppression of macrophage antimicrobial activity by a tumor cell product. J Immunol 1983, 131:384–387.PubMedGoogle Scholar
  26. 26.
    Nathan CF, Tsunawaki S. Secretion of toxic oxygen products by macrophages: regulatory cytokines and their effects on the oxidase. In: Biochemistry of Macrophages. Pitman, London (Ciba Foundation Symposium 118) 1986, pp. 211–230.Google Scholar
  27. 27.
    Nathan CF, Hibbs JB Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opinion Immunol 1991, 3:65–70.CrossRefGoogle Scholar
  28. 28.
    Stuehr DJ, Griffith OW. Mammalian synthesis of nitric oxide. Adv Enzymol Rel Areas Mol Biol 1991, in press.Google Scholar
  29. 29.
    Ding A, Nathan C, Graycar J, Derynck R, Stuehr DJ, Srimal S. Macrophage deactivating factor and transforming growth factors-βl, -132, and β3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-γ. J Immunol 1990, 145:940–944.PubMedGoogle Scholar
  30. 30.
    Beutler B, Cerami A. The biology of cachectin/TNFa: A primary mediator of the host response. Ann Rev Immunol 1989, 7:625–655.CrossRefGoogle Scholar
  31. 31.
    Larrick JW, Wright SC. Cytotoxic mechanism of tumor necrosis factor-a. FASEB J 1990, 4:3215–3222.PubMedGoogle Scholar
  32. 32.
    Scheurich P, Thoma B, Ücer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF) a: induction of TNF receptors on human T cells and TNFα-mediated enhancement of T cell responses. J Immunol 1987, 138:1786PubMedGoogle Scholar
  33. 33.
    Ranges GE, Figari IS, Espevik T, and Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor-β and reversal by tumor necrosis factor-a. J Exp Med 1987, 166:9918998.Google Scholar
  34. 34.
    Mace KF, Ehrke MJ, Hori K, Maccubbin DL and Mihich E. Role of tumor necrosis factor in macrophage activation and tumoricidal activity. Cancer Res 1988, 48:5427– 5432.PubMedGoogle Scholar
  35. 35.
    Belosevic M, Finbloom DS, Meltzer MS, Nacy CA. IL2. A cofactor for induction of activated macrophage resistance to infection. J Immunol 1990, 145:831–839.PubMedGoogle Scholar
  36. 36.
    Stenger S, Solbach W, Rollinghoff M, Bogdan C. Cytokine interactions in experimental cutaneous leishmaniasis. II. Both interleukin 4 and interferon -γ induce macrophages to produce tumor necrosis factor α, which accounts for the synergistic antiparasitic effect of IL-4 and IFN-γ . Eur J Immunol 1991, 21:1669–1675.PubMedCrossRefGoogle Scholar
  37. 37.
    Murray HW, Juangbhanich CW, Nathan CF, Cohn ZA. Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J Exp Med 1979, 150:950–964.PubMedCrossRefGoogle Scholar
  38. 38.
    Adams LB, Hibbs JB Jr, Taintor RR, Krahenbuhl JL. Microbiostatic effect of murine activated macrophages for Toxoplasma gondii. Role for synthesis of inorganic nitrogen oxides from L-arginine. J Immunol 1990, 144:2725–2729.PubMedGoogle Scholar
  39. 39.
    Murray HW. Cell-mediated immune response in experimental visceral leishmaniasis. II. Oxygen-dependent killing of intracellular Leishmania donovani amastigotes. J. Immunol 1982, 129:351–357.PubMedGoogle Scholar
  40. 40.
    Green SJ, Meltzer MS, Hibbs JB Jr, Nacy CA. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol 1990, 144:278–283.PubMedGoogle Scholar
  41. 41.
    Liew FY, Millott S, Parkinson C, Palmer RMJ, Moncada S. Macrophage killing of leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 1990, 144:4794–4797.PubMedGoogle Scholar
  42. 42.
    Mauel J, Ransijn A, Buchmüller-Rouiller Y. Killing of leishmania parasites in activated murine macrophages is based on an L-arginine-dependent process that produces nitrogen derivatives. J. Leukocyte Biol., 1991, 49:73–82.PubMedGoogle Scholar
  43. 43.
    Bogdan C, Stenger S, Röllinghoff M, Solbach W. Cytokine interactions in experimental cutaneous leishmaniasis. Interleukin 4 synergizes with interferon γ to activate murine macrophages for killing of L. major amastigotes. Eur J Immunol 1991, 21:327–333.PubMedCrossRefGoogle Scholar
  44. 44.
    Bogdan C, Moll H, Röllinghoff M, Solbach W. Tumor necrosis factor-a in combination with interferon--γ , but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur J Immunol 1990, 20:1131–1135.PubMedCrossRefGoogle Scholar
  45. 45.
    Chang HR, Grau GE, Pechere JC. Role of TNF and IL-1 in infections with Toxoplasma gondii. Immunology 1990, 69:33–37.PubMedGoogle Scholar
  46. 46.
    Tsunawaki S, Sporn M, Ding A, Nathan CF. Deactivation of macrophages by transforming growth factor-β. Nature 1988, 334:260–262.PubMedCrossRefGoogle Scholar
  47. 47.
    Lehn M, Weiser WY, Engelhorn S, Gillis S, Remold HG. IL-4 inhibits H202 production and antileishmanial capacity of human cultured monocytes mediated by IFN-γ . J Immunol 1989, 143:3020–3024.PubMedGoogle Scholar
  48. 48.
    Abramson SL, Gallin JI. Il-4 inhibits superoxide production by human mononuclear phagocytes. J Immunol 1990, 144:625–630.PubMedGoogle Scholar
  49. 49.
    Essner R, Rhoades K, McBride WH, Morton DL, Economou JS. IL-4 downregulates IL-1 and TNF gene expression in human monocytes. J Immunol 1989, 142:3857–3861.PubMedGoogle Scholar
  50. 50.
    Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor α, interleukin 1, and prostaglandin E2 Proc Natl Acad Sci USA 1989, 86:3803–3807.PubMedCrossRefGoogle Scholar
  51. 51.
    Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 1988, 141:2407–2412.PubMedGoogle Scholar
  52. 52.
    Somers SD, Erickson KL. Regulation of murine macrophage function by IL-4. I. Activation of macrophages by a T-T cell hybridoma is due to IL-4. Cell Immunol 1989, 122:178–187.PubMedCrossRefGoogle Scholar
  53. 53.
    Nong YH, Titus RG, Ribeiro JMC, Remold HG. Peptides encoded by the calcitonin gene inhibit macrophage function. J Immunol 1989, 143:45–49.PubMedGoogle Scholar
  54. 54.
    Hasday JD, Shah EM, Lieberman AP. Macrophage tumor necrosis factor-a release is induced by contact with some tumors. J Immunol 1990, 145:371–379.PubMedGoogle Scholar
  55. 55.
    Descoteaux A, Matlashewski G. c-fos and tumor necrosis factor gene expression in Leishmania donovani-infected macrophages. Mol Cell Biol 1989, 9:5223–5227.PubMedGoogle Scholar
  56. 56.
    Reiner NE, Ng W, Wilson CB, McMaster WR, Burchett SK. Modulation of in vitro cytokine responses to Leishmania donovani. Interferon γ prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to leishmania by producing both tumor necrosis factor a and interleukin 1. J Clin Invest 1990, 85:1914–1924.PubMedCrossRefGoogle Scholar
  57. 57.
    Reiner NE, Ng W, Ma T, McMaster WR. Kinetics of -γ — interferon binding and induction of major histocompatibility complex class II mRNA in leishmania-infected macrophages. Proc Natl Acad Sci 1988, 45:4330–4335.CrossRefGoogle Scholar
  58. 58.
    Engelhorn S, Bruckner A, Remold HG. A soluble factor produced by inoculation of human monocytes with Leishmania donovani promastigotes suppresses IFNγ-dependent monocyte activation. J Immunol 1990, 145:2662– 2668.PubMedGoogle Scholar
  59. 59.
    Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein Barr virus gene BCRF1. Science 1990, 248:1230–1233.PubMedCrossRefGoogle Scholar
  60. 60.
    Hsu DH, de Waal Malefyt R, Fiorentino DF, Dang MN, Vieira P, deVries J, Spits H, Mosmann TR, Moore KW. Expression of interleukin 10 activity by Epstein Barr virus protein BCRF1. Science 1990, 250:830–832.PubMedCrossRefGoogle Scholar
  61. 61.
    Gosselin J, Menezes J, D’Addario M, Hiscott J, Flamand L, Lamoureux G, Oth D. Inhibition of tumor necrosis factor-a transcription by Epstein-Barr virus. Eur J Immunol 1991, 21:203–208.PubMedCrossRefGoogle Scholar
  62. 33.
    Ranges GE, Figari IS, Espevik T, and Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor-β and reversal by tumor necrosis factor-a. J Exp Med 1987, 166:9918998.Google Scholar
  63. 34.
    Mace KF, Ehrke MJ, Hori K, Maccubbin DL and Mihich E. Role of tumor necrosis factor in macrophage activation and tumoricidal activity. Cancer Res 1988, 48:5427–5432.PubMedGoogle Scholar
  64. 35.
    Belosevic M, Finbloom DS, Meltzer MS, Nacy CA. IL2. A cofactor for induction of activated macrophage resistance to infection. J Immunol 1990, 145:831–839.PubMedGoogle Scholar
  65. 36.
    Stenger S, Solbach W, Rollinghoff M, Bogdan C. Cytokine interactions in experimental cutaneous leishmaniasis. II. Both interleukin 4 and interferon -γ induce macrophages to produce tumor necrosis factor α, which accounts for the synergistic antiparasitic effect of IL-4 and IFN-γ . Eur J Immunol 1991, 21:1669–1675.PubMedCrossRefGoogle Scholar
  66. 37.
    Murray HW, Juangbhanich CW, Nathan CF, Cohn ZA. Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J Exp Med 1979, 150:950–964.PubMedCrossRefGoogle Scholar
  67. 38.
    Adams LB, Hibbs JB Jr, Taintor RR, Krahenbuhl JL. Microbiostatic effect of murine activated macrophages for Toxoplasma gondii. Role for synthesis of inorganic nitrogen oxides from L-arginine. J Immunol 1990, 144:2725–2729.PubMedGoogle Scholar
  68. 39.
    Murray HW. Cell-mediated immune response in experimental visceral leishmaniasis. II. Oxygen-dependent killing of intracellular Leishmania donovani amastigotes. J. Immunol 1982, 129:351–357.PubMedGoogle Scholar
  69. 40.
    Green SJ, Meltzer MS, Hibbs JB Jr, Nacy CA. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol 1990, 144:278–283.PubMedGoogle Scholar
  70. 41.
    Liew FY, Millott S, Parkinson C, Palmer RMJ, Moncada S. Macrophage killing of leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 1990, 144:4794–4797.PubMedGoogle Scholar
  71. 42.
    Mauel J, Ransijn A, Buchmüller-Rouiller Y. Killing of leishmania parasites in activated murine macrophages is based on an L-arginine-dependent process that produces nitrogen derivatives. J. Leukocyte Biol., 1991, 49:73–82.PubMedGoogle Scholar
  72. 43.
    Bogdan C, Stenger S, Röllinghoff M, Solbach W. Cytokine interactions in experimental cutaneous leishmaniasis. Interleukin 4 synergizes with interferon γ to activate murine macrophages for killing of L. major amastigotes. Eur J Immunol 1991, 21:327–333.PubMedCrossRefGoogle Scholar
  73. 44.
    Bogdan C, Moll H, Röllinghoff M, Solbach W. Tumor necrosis factor-a in combination with interferon--γ , but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur J Immunol 1990, 20:1131–1135.PubMedCrossRefGoogle Scholar
  74. 45.
    Chang HR, Grau GE, Pechere JC. Role of TNF and IL-1 in infections with Toxoplasma gondii. Immunology 1990, 69:33–37.PubMedGoogle Scholar
  75. 46.
    Tsunawaki S, Sporn M, Ding A, Nathan CF. Deactivation of macrophages by transforming growth factor-β. Nature 1988, 334:260–262.PubMedCrossRefGoogle Scholar
  76. 47.
    Lehn M, Weiser WY, Engelhorn S, Gillis S, Remold HG. IL-4 inhibits H202 production and antileishmanial capacity of human cultured monocytes mediated by IFN-γ . J Immunol 1989, 143:3020–3024.PubMedGoogle Scholar
  77. 48.
    Abramson SL, Gallin JI. Il-4 inhibits superoxide production by human mononuclear phagocytes. J Immunol 1990, 144:625–630.PubMedGoogle Scholar
  78. 49.
    Essner R, Rhoades K, McBride WH, Morton DL, Economou JS. IL-4 downregulates IL-1 and TNF gene expression in human monocytes. J Immunol 1989, 142:3857–3861.PubMedGoogle Scholar
  79. 50.
    Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor α, interleukin 1, and prostaglandin E2 Proc Natl Acad Sci USA 1989, 86:3803–3807.PubMedCrossRefGoogle Scholar
  80. 51.
    Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 1988, 141:2407–2412.PubMedGoogle Scholar
  81. 52.
    Somers SD, Erickson KL. Regulation of murine macrophage function by IL-4. I. Activation of macrophages by a T-T cell hybridoma is due to IL-4. Cell Immunol 1989, 122:178–187.PubMedCrossRefGoogle Scholar
  82. 53.
    Nong YH, Titus RG, Ribeiro JMC, Remold HG. Peptides encoded by the calcitonin gene inhibit macrophage function. J Immunol 1989, 143:45–49.PubMedGoogle Scholar
  83. 54.
    Hasday JD, Shah EM, Lieberman AP. Macrophage tumor necrosis factor-a release is induced by contact with some tumors. J Immunol 1990, 145:371–379.PubMedGoogle Scholar
  84. 55.
    Descoteaux A, Matlashewski G. c-fos and tumor necrosis factor gene expression in Leishmania donovani-infected macrophages. Mol Cell Biol 1989, 9:5223–5227.PubMedGoogle Scholar
  85. 56.
    Reiner NE, Ng W, Wilson CB, McMaster WR, Burchett SK. Modulation of in vitro cytokine responses to Leishmania donovani. Interferon γ prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to leishmania by producing both tumor necrosis factor a and interleukin 1. J Clin Invest 1990, 85:1914–1924.PubMedCrossRefGoogle Scholar
  86. 57.
    Reiner NE, Ng W, Ma T, McMaster WR. Kinetics of -γ — interferon binding and induction of major histocompatibility complex class II mRNA in leishmania-infected macrophages. Proc Natl Acad Sci 1988, 45:4330–4335.CrossRefGoogle Scholar
  87. 58.
    Engelhorn S, Bruckner A, Remold HG. A soluble factor produced by inoculation of human monocytes with Leishmania donovani promastigotes suppresses IFNγ-dependent monocyte activation. J Immunol 1990, 145:2662–2668.PubMedGoogle Scholar
  88. 59.
    Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein Barr virus gene BCRF1. Science 1990, 248:1230–1233.PubMedCrossRefGoogle Scholar
  89. 60.
    Hsu DH, de Waal Malefyt R, Fiorentino DF, Dang MN, Vieira P, deVries J, Spits H, Mosmann TR, Moore KW. Expression of interleukin 10 activity by Epstein Barr virus protein BCRF1. Science 1990, 250:830–832.PubMedCrossRefGoogle Scholar
  90. 61.
    Gosselin J, Menezes J, D’Addario M, Hiscott J, Flamand L, Lamoureux G, Oth D. Inhibition of tumor necrosis factor-a transcription by Epstein-Barr virus. Eur J Immunol 1991, 21:203–208.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1992

Authors and Affiliations

  • C. Bogdan
  • Y. Vodovotz
  • C. F. Nathan

There are no affiliations available

Personalised recommendations